Drug Profile
Chlorhexidine - GSK
Alternative Names: Clorhexidine gel - GSK ; Corsodyl; UmbiproLatest Information Update: 10 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Anti-infectives; Antiseptics; Biguanides; Small molecules
- Mechanism of Action Cell wall modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Infections
Most Recent Events
- 15 Oct 2018 No recent reports on development identified- phase III for Infections (In neonates) in Nepal (Topical)
- 15 Oct 2018 No recent reports on development identified- preregistration for Infections (In neonates) in European Union (Topical)
- 29 Apr 2016 The Committee for Medicinal Products for Human Use recommends approval (under Article 58 procedure) of Chlorhexidine gel (7.1% chlorhexidine digluconate gel, equivalent to 4% chlorhexidine) for Infections (in neonates) in markets outside EU